Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

JZP926

Other · developed by Jazz Pharmaceuticals

Phase 2/3 Most advanced trial

JAZZ Developer

1 Registered trials

What is JZP926?

JZP926 is an investigational drug studied in Juvenile Myoclonic Epilepsy.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Jazz Pharmaceuticals (JAZZ)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07723963	Phase 2/3	Juvenile Myoclonic Epilepsy	Recruiting	JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Juvenile Myoclonic Epilepsy

More from Jazz Pharmaceuticals

Asparaginase Erwinia chrysanthemi FDA approved Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 Flezurafenib Phase 1 JZP269 Phase 1 Nabiximols Phase 2 ONC206 Phase 2

Sources

ClinicalTrials.gov NCT07723963

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind JZP926

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z